Deciding Between Active Surveillance and Targeted Therapy in BRCA+ Prostate Cancer
Leonard G. Gomella, MD, discusses deciding between active surveillance and precision medicine in mutated prostate cancer.
Related Articles
FDA Grants Accelerated Approval to Tovorafenib in Pediatric Low-Grade Glioma
The FDA has approved the new drug application of tovorafenib for the treatment of pediatric low-grade glioma.
Patient Case: Pathology of Graft Versus Host Disease
Yi-Bin Chen, MD, presents a patient case, detailing the symptomology and pathology of graft versus host disease, such as dry eyes, dry mouth, and difficulty…
Combating Resistance Mechanisms to Treatment in Thyroid Cancer
Lova Sun, MD, MSCE, discusses resistance mechanisms against targeted agents for the treatment of thyroid cancer.
FDA Grants Accelerated Approval to Tovorafenib in Pediatric Low-Grade Glioma
The FDA has approved the new drug application of tovorafenib for the treatment of pediatric low-grade glioma.
FDA Approves 177Lu-Dotatate in Patients 12 and Up for GEP-NETs
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
FDA Approves 177Lu-Dotatate in Patients 12 and Up for GEP-NETs
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Powell Reviews Updated IO/TKI Data and AE Management in Endometrial Cancer
During a Case-Based Roundtable® event, Matthew A. Powell, MD, discussed the case of a patient with advanced endometrial cancer treated with lenvatinib plus pembrolizumab who experienced…
Sanjay Juneja: ‘When There Is a Need and You Can, You Should’
In the interview with Targeted Oncology, Sanjay K. Juneja, MD, 2024 Oncology Icons honoree, discusses the transformative power of collaboration, technology, and compassionate care in…
Real-World Analysis Shows Promising Outcomes, Safety With Ibrutinib in CLL
A 2-year follow-up study showed that ibrutinib maintained efficacy and safety among patients with chronic lymphocytic leukemia, highlighting its importance in the field.
Axatilimab Trial Results
Evaluating the significance of the AGAVE-201 trial results for axatilimab in refractory chronic GvHD and key factors to consider when assessing the data.